Top Story Today
The FDA Declared War on Cheap Ozempic Knockoffs, and It Named Names
The FDA announced it will take "decisive steps" to restrict compounded GLP-1 drugs, explicitly calling out Hims & Hers and threatening product seizures and injunctions. The crackdown effectively ends the gray market era where telehealth startups sold cheap knockoff versions of Ozempic and Wegovy. Hims, which derived a significant share of its online revenue from GLP-1 medications, has already guided to a $65 million Q1 revenue hit and pivoted to selling branded Novo Nordisk products instead. For Novo and Lilly, every patient pushed off a compounded product is revenue recaptured; for millions of uninsured patients, affordable access just got a lot harder.
Why it matters: This regulatory pivot reshapes the multi-billion-dollar compounded GLP-1 market overnight, strengthening the branded duopoly's pricing power while raising urgent questions about patient access to obesity treatments that can cost over $1,000 a month without insurance.
Read more →The Obesity Drug Wars
Roche Just Crashed the Obesity Party With a 22.5% Weight Loss Number
Roche's $2.7 billion bet on Carmot Therapeutics is paying off. Its injectable enicepatide posted 22.5% weight loss in 48 weeks, matching Eli Lilly's Zepbound in roughly half the trial duration, with no signs of a plateau. Roche is building a five-asset obesity franchise and has broken ground on a $700 million manufacturing plant. Phase 3 trials start this year.
Read more →Lilly's Next Obesity Drug Might Actually Replace Your CPAP Machine
Retatrutide, Lilly's triple-receptor obesity drug, cut sleep apnea severity by 60.6% in Phase 3, topping its own Zepbound's results. Patients averaged 28.3% body weight loss at 80 weeks. Lilly is positioning retatrutide as a platform therapy across sleep apnea, osteoarthritis, diabetes, and more, with seven additional Phase 3 readouts expected this year.
Read more →Wegovy Ditched the Needle in the UK, and the Oral GLP-1 Race Is On
The UK approved the first GLP-1 pill for weight loss: oral Wegovy, which delivered 16.6% weight loss in trials, nearly matching the injectable. Novo Nordisk expects private prescriptions within weeks. With Lilly's oral orforglipron already FDA-approved and Viking Therapeutics posting strong Phase 2 data, the oral obesity market is becoming pharma's fiercest battleground.
Read more →Millions of Women Take Ozempic. A Harvard Study Addresses What Happens If They Get Pregnant
A Harvard analysis of 3,572 pregnancies found that accidental GLP-1 exposure in early pregnancy didn't significantly raise miscarriage or birth defect rates. The gap between exposed and unexposed women was just 2.6 percentage points (not statistically significant). It's reassurance, not a green light: labels still say stop before conception.
Read more →Deals and Dollars
Roche Paid $700M Upfront for a Drug That Destroys Its Target
Roche struck a deal worth up to $2.3 billion with Nurix Therapeutics for bexobrutideg, a drug that physically destroys the BTK protein instead of just blocking it. In early trials, 83% of heavily pretreated CLL patients responded. The 50/50 U.S. profit split signals Roche sees blockbuster potential, and the deal cements protein degradation as big pharma's hottest modality.
Read more →Summit Tried to Raise $500M. It Lasted One Day.
Summit Therapeutics launched a $500 million stock offering and killed it within 48 hours after shares cratered to a 52-week low. The biotech has raised over $1 billion in recent years to fund ivonescimab, a cancer drug with promising head-to-head data against Keytruda. With an FDA decision looming in November, the financing question isn't going away.
Read more →Regulatory and Policy
CMS Just Made Big Pharma's Pricing Nightmare More Permanent
CMS proposed locking in Medicare-negotiated drug prices with sharply limited renegotiation options. Manufacturers can only reopen a deal if a drug gains a major new indication or pricing factors shift by at least 15%. For companies with aging blockbusters like Eliquis and Stelara, the IRA's pricing cliff just became a permanent step-down.
Read more →Amgen's Tavneos Faces a Jury of Scientists
The FDA proposed withdrawing Tavneos from the market, alleging the original trial data was manipulated by re-reviewing just 9 of 331 patients to flip a failed result. Amgen's response: commission Duke University to independently re-analyze the data, with results due June 29. Whether good data can redeem a compromised process could set a precedent for the entire industry.
Read more →Whoop Just Picked a Fight With the FDA Over Blood Pressure
The $10.1 billion wearable company is defying an FDA warning letter, insisting its blood pressure feature is wellness, not medicine. The FDA calls it an unapproved medical device. Apple and Samsung took the regulatory path; Whoop is betting it can win a showdown. The outcome could redraw the line between fitness trackers and regulated devices for the entire wearables industry.
Read more →